Partnership to Develop Atherosclerosis Detection

Optina Diagnostics Logo, Courtesy of Optina Diagnostics

Register to receive a free Peripheral Vascular Devices Market Analysis, Size, and Trends Report synopsis and brochure.

In a new partnership following a proof of concept study, Optina Diagnostics and the Montreal Heart Institute are working on developing a new biomarker for the detection of atherosclerosis. Atherosclerosis is a disease where plaque builds up on the wall of arteries, which then thicken and harden. If left undiagnosed and untreated, the hardened arteries can limit blood flow to the brain and can lead to vascular dementia. The biomarker can be used to assess patients in a more non-invasive manner than other devices in the market, such as stents and balloon catheters.

According to iData Research’s analysis of the peripheral vascular device market, favorable reimbursement continues to drive procedure volume in the office-based lab (OBL) setting, causing price erosion across multiple market segments. OBLs are privately owned and are more price sensitive than hospitals. This has had a negative impact across all peripheral vascular devices sold to OBLs. While other segments of the market are experiencing a decrease in growth, the biomarker is a unique product offering. The device is non-invasive, compared to other diagnostic tools, so this generates an opportunity create positive growth, as it is suitable for an office-based lab setting.

David Lapoint, CEO of Optina Diagnostics stated that the “main objective is to provide retinal biomarker information to allow for the characterization of patients suffering from memory loss in a non-invasive manner” said David Lapointe, CEO Optina Diagnostics.”

Dr. Jean-Claude Tardif’s research group from the Montreal Heart Institute has stated that “currently, the study of arteries is limited by the cost and/or the invasiveness of imaging procedures. Optina’s eye test is a simple technology that would allow for the non-invasive detection of biomarkers that could be used in the assessment of patients and potentially help prevent heart attacks, strokes, and peripheral vascular disease. That is why we are very excited with the results of our proof of concept study and are ready to continue this promising clinical research project in a much larger patient cohort.”


For Further Information

To get in an in-depth market overview, as well as insight through primary research and procedural volumes from 19 countries, please read iData Research’s’ 2958 page Peripheral Vascular Devices Market Analysis, Size, and Trends Report.

Leave a Reply